Anika Therapeutics (ANIK) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,450.00%. A quarter ago, it was expected that this medical technology company would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of +100%.Over the last four ...

Profitability improved in the quarter, with GAAP gross margin rising to 63% from 56% a year earlier, reflecting a more favorable mix and higher volumes that improved manufacturing throughput and productivity. Operating expenses were $18.5 million , up from $17.8 million , with SG&A increasing on higher sales and marketing spending tied primarily to Integrity growth, while R&D held flat at $6.5 million .OEM channel revenue was $17.3 million , down 12% year-over-year. Management pointed to lower year-over-yea ...

Anika Therapeutics (NasdaqGS:ANIK) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsIan W. McLeod - SVP, Chief Accounting Officer and TreasurerMatt Hall - Executive Director of Corporate Development and Investor RelationsSteve Griffin - President and CEOConference Call ParticipantsAnderson Schock - MedTech Equity Research AnalystMichael Petusky - Managing Director and Senior Research AnalystOperatorGood morning, ladies and gentlemen, and welcome to Anika's fourth quarter and year-end ...

Anika Therapeutics (NasdaqGS:ANIK) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsIan W. McLeod - SVP, Chief Accounting Officer and TreasurerMatt Hall - Executive Director of Corporate Development and Investor RelationsSteve Griffin - President and CEOConference Call ParticipantsAnderson Schock - MedTech Equity Research AnalystMichael Petusky - Managing Director and Senior Research AnalystOperatorGood morning, ladies and gentlemen, and welcome to Anika's Q4 and year-end earnings con ...

Anika Therapeutics (NasdaqGS:ANIK) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker4Good morning, ladies and gentlemen, and welcome to Anika's fourth quarter and year-end earnings conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, February 26, 2026. I would now ...

Q4 AND FULL YEAR 2025 EARNINGS CALL Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Se ...

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA ...

Group 1 - Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedics, with a presentation scheduled at the Canaccord Genuity 2026 Musculoskeletal Conference on March 2, 2026 [1] - The presentation will be available via live webcast and archived for 30 days, allowing investors to access the information post-event [2] - Anika specializes in minimally invasive orthopedic products, particularly in Osteoarthritis Pain Management and Regenerative Solutions, leveraging expertise in hyaluronic acid and implant solutions [3] Group 2 - Anika's global operations are headquartered outside of Boston, Massachusetts, emphasizing its strategic location for industry engagement [3] - The company actively engages with investors through one-on-one meetings during events, showcasing its commitment to investor relations [1][2]

Core Viewpoint - Anika Therapeutics, Inc. will release its fourth quarter and year-end 2025 financial results on February 26, 2026, followed by a conference call to discuss the results and business highlights [1]. Group 1: Financial Results Announcement - The financial results will be issued before the market opens on February 26, 2026 [1]. - A conference call is scheduled for 8:30 a.m. ET on the same day to discuss the results [1]. Group 2: Conference Call Access - The conference call can be accessed via a toll-free domestic number (1-800-717-1738) or an international number (1-646-307-1865) with the conference ID number 89327 [2]. - A live audio webcast and presentation materials will be available on Anika's Investor Relations website [2]. - The call will be archived and accessible shortly after its conclusion on the same website [2]. Group 3: Company Overview - Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedic care [3]. - The company specializes in hyaluronic acid and implant solutions, partnering with clinicians to provide minimally invasive products [3]. - Anika targets high opportunity areas within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, with products delivered in key care sites like ambulatory surgery centers [3]. - The company's global operations are headquartered outside of Boston, Massachusetts [3].

Core Viewpoint - Anika Therapeutics, Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and other unlawful business practices related to its senior management [1]. Group 1: Company Performance - On July 30, 2025, Anika announced topline results from its clinical trial of Hyalofast, which is a resorbable hyaluronic acid scaffold for cartilage repair. The results indicated that while Hyalofast showed consistent improvements in treated patients compared to microfracture, it did not meet its pre-specified co-primary endpoints [2]. - The clinical trial's outcomes were likely affected by a higher dropout rate in the microfracture arm and missed visits during COVID, leading to missing data that complicated the statistical analysis [2]. - Following the announcement, Anika's share price fell by $3.06, or approximately 27.42%, closing at $8.10 per share on the same day [2]. Group 2: Legal Investigation - The ongoing investigation aims to determine if claims can be filed under federal securities laws, although no lawsuit has been initiated yet [3]. - Investors who purchased or acquired Anika securities and have relevant information are encouraged to contact Kirby McInerney LLP for further discussion regarding their rights or interests [3].